NCT05660122View on ClinicalTrials.gov

A Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab

CompletedOBSERVATIONAL
Enrollment

2,852

Participants

Timeline

Start Date

November 11, 2022

Primary Completion Date

December 26, 2024

Study Completion Date

August 11, 2025

Conditions
Gastroesophageal Reflux Disease
Interventions
DRUG

Fexuprazan Hydrochloride

Fexuclue Tablet 40mg

Trial Locations (1)

Unknown

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY